AZ RSV Drug 

Airfinity analysis shows Astrazeneca's monoclonal infant RSV drug could be administered to up to 3.5 million infants under one year of age in Europe once approved which would generate a potential revenue of up to $1.1bn. 

cdc-fx9RJgZYRUE-unsplash

AstraZeneca’s infant RSV drug Beyfortus could generate $1.1bn sales revenue

Nature 060922

How nasal-spray vaccines could change the pandemic

Cinco Dias Aug 22

Airfinity estimates a shortage of up to 55 million monkeypox vaccine doses

Airfinity analysis shows the potential global demand for the monkeypox vaccine under three potential demand scenarios. 

syringes-g3418b9fd4 1920

18 million monkeypox vaccines needed to protect most at risk, 85 million to protect wider gay community and health workers

Tx Therapeutics webinar (1)

Global Supply and Demand: The future of the antivirals landscape

Lead Analyst and Head of Therapeutics, Dr Arsalan Azad, hosts an exclusive session on antiviral supply and demand, sharing Airfinity’s independent analysis and forecasts on the treatment landscape.

AstraZeneca and Pfizer/BioNTech saved over 12 million lives in the first year of vaccination

Analysis by Airfinity shows the AstraZeneca and Pfizer/BioNTech vaccines saved the most lives in the first year of the global vaccination campaign.

mat-napo-pIJ34ZrZEEw-unsplash

d41586-022-02140-w 23345400

Long-COVID treatments: why the world is still waiting

Q2 Treatments Revenue Forecast 2022

Q2 Treatments Revenue Forecast 2022 2

Airfinity’s latest revenue forecast for COVID-19 antivirals shows the greater availability of Paxlovid may have driven down demand for Molnupiravir.

forbes paxlovid

Sales of COVID-19 antiviral pill Paxlovid to leap frog Merck’s competitor Molnupiravir

Airfinity would like to extend a warm welcome to our first ever Chief Product Officer, Colin Williams. 

Newsroom

Featured